ASH Annual Meeting and Exposition | Conference

ADC Targeting CD123 Active in R/R AML and BPDCN

December 18th 2019

IMGN632, an investigational anti-CD123 antibody-drug conjugate, demonstrated preliminary activity in patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm.

Resistance-Targeting BTK Inhibitor ARQ 531 Active Across B-Cell Malignancies

December 17th 2019

The investigational Bruton tyrosine kinase inhibitor ARQ 531 demonstrated safety and clinical activity across a range of B-cell malignancies.

Large PFS Gain With Daratumumab in Transplant-Ineligible Myeloma

December 11th 2019

More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.

Updated bb21217 Data Continue to Impress in Multiple Myeloma

December 11th 2019

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

December 11th 2019

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).

Bispecific Antibody Shows High Clinical Activity in Heavily Pretreated NHL

December 11th 2019

REGN1979 demonstrated antitumor activity with an acceptable safety profile in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Addition of BET Inhibitor to Ruxolitinib Reduces Spleen Volume, Improves Symptoms in Myelofibrosis

December 11th 2019

The addition of CP-0610 to ruxolitinib (Jakafi) in JAK inhibitor-naïve patients with myelofibrosis induced splenic and symptomatic responses as early as 12 weeks.

Tisagenlecleucel Demonstrates Real-World Clinical Benefit in DLBCL

December 10th 2019

The CAR T-cell therapy tisagenlecleucel (Kymriah) showed similar real-world efficacy and safety findings to that of the JULIET trial in the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Daratumumab Boosts Outcomes in Transplant-Eligible Myeloma

December 10th 2019

Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.

Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis

December 10th 2019

Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.

Identification of Prognostic Constellations of Driver Mutations in AML and MDS

December 10th 2019

Ilaria Iacobucci, PhD, staff scientist, St. Jude Children’s Research Hospital, discusses the use of integrated transcriptomic and genomic sequencing in identifying prognostic constellations of driver mutations in acute myeloid leukemia and myelodysplastic syndromes.

Dr. Brown on Blinatumomab Versus Chemotherapy as Post-Reinduction Therapy in B-ALL

December 10th 2019

Patrick Brown, MD, chair of NCCN Guidelines for Adult and Pediatric ALL, and director of the Pediatric Leukemia Program at Sidney Kimmel Comprehensive Cancer Center, discusses the results of the randomized phase III Children’s Oncology Group Study AALL1331 trial of blinatumomab (Blincyto) versus chemotherapy as post-reinduction therapy in high- and intermediate-risk children and young adults with B-acute lymphoblastic leukemia in first relapse.

Daratumumab Plus Carfilzomib and Dexamethasone Extends PFS in Relapsed/Refractory Myeloma

December 10th 2019

Adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Maintenance CC-486 Improves Survival for Older Patients With AML

December 10th 2019

Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.

Blinatumomab as Post-Reinduction Therapy Improves Survival in Pediatric and AYA B-ALL

December 10th 2019

Blinatumomab (Blincyto) as post-reinduction consolidation therapy before hematopoietic stem cell transplantation improved disease-free survival and overall survival by approximately 20% compared with intensive chemotherapy in pediatric and adolescent and young adult patients with high- or intermediate-risk of first relapse of B-cell acute lymphoblastic leukemia.

Enasidenib Plus Azacitidine Significantly Improves Responses in Newly Diagnosed IDH2-Mutated AML

December 10th 2019

Enasidenib significantly improves complete remission and overall response when combined with azacitidine compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia with IDH2 mutations.

KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

December 10th 2019

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up

December 10th 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis

December 10th 2019

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.

Patients with B-Cell Malignancies Experience Stable Disease on Vecabrutinib Therapy

December 10th 2019

Vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, exhibited evidence of clinical activity in adults with B-cell malignancies without producing any grade ≥3 treatment-related adverse events.